2 months Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Outperform” Rating from Royal Bank of Canada MarketBeat
Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday.
Canada · Nasdaq 100 · Pharmaceuticals · Regeneron Pharma (REGN) · Royal Bank of Canada · Science
X